Pelthos Therapeutics Inc.
$25.92 -$2.48 (-8.73%) 1D Market openKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Apr 6
The stock moved +19.5% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Apr 6 -
Feb 27
The stock moved +14.6% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Feb 27 -
Feb 17
From its Jan 29 high, the share price fell 29%.
Peak close $25.78 on Jan 29; trough close $18.19 on Feb 17. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -29%
The story updates itself as events post · The wolf reports; you decide
Snapshot
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.